PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Baricitinib - Alopecia
PAD Profile : Baricitinib - Alopecia
Keywords :
alopecia areata, NICE,
Brand Names Include :
Olumiant
Traffic Light Status
Status 1 of 1.
Status :
Non Formulary
Formulations :
- Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Type
Document
Review Date
Guidelines
No guidelines returned.
Other Drugs
Other Indications
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
01 November 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed that baricitinib for severe alopecia areata will be given a NON-FORMULARY traffic light status following publication of NICE TA926.
Baricitinib is not recommended, by NICE, within its marketing authorisation, for treating this indication.
Associated BNF Codes
13. Skin
13.05.03. Drugs affecting the immune response